NEWS HIGHLIGHTS
Published Studies Related to Alinia (Nitazoxanide)
Nitazoxanide for the empiric treatment of pediatric infectious diarrhea. [2012]
We conducted a double-blind, placebo-controlled clinical trial to demonstrate the
efficacy of nitazoxanide suspension for the treatment of presumed infectious
diarrhea in children... These results suggest nitazoxanide may be a viable therapeutic
option for the empiric treatment of diarrheal illness in children where the
etiology is unknown or presumed to be of infectious origin.
A Randomized Study Comparing Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline versus Triple Therapy for the Eradication of Helicobacter pylori. [2011.11]
OBJECTIVES: Resistance to standard Helicobacter pylori (HP) treatment regimens has led to unsatisfactory cure rates in HP-infected patients. This study was designed to evaluate a novel four-drug regimen (three antibiotics and a proton pump inhibitor (PPI)) for eradication of HP infection in treatment-naive patients... CONCLUSIONS: This open-label, prospective trial demonstrates that LOAD is a highly active regimen for the treatment of HP in treatment-naive patients. A large randomized controlled trial is warranted to further evaluate the efficacy of this regimen.
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. [2009.12.02]
BACKGROUND: Treatment of cryptosporidiosis in HIV infected children has proved difficult and unsatisfactory with no drugs having demonstrable efficacy in controlled trials except nitazoxanide. We hypothesised that a prolonged course of treatment with high dose nitazoxanide would be effective in treating cryptosporidiosis in HIV positive Zambian children... CONCLUSION: We found no significant benefit in children with cryptosporidiosis despite high dose and longer treatment duration. This is the second randomised controlled trial to suggest that in Zambian children with HIV-related immunosuppression nitazoxanide does not eradicate this infection nor provide clinical symptom reduction. TRIAL REGISTRATION: The trial was registered as ISRCTN41089957.
Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. [2009.07]
BACKGROUND: In previous studies, nitazoxanide has demonstrated a cytoprotective effect against rotavirus, reducing the duration of diarrhea in comparison to placebo. We designed a randomized, single-blind, controlled trial in order to assess the effectiveness of nitazoxanide and probiotics in comparison with a control group... CONCLUSIONS: Treatment with nitazoxanide and probiotics is effective in the management of children with acute rotavirus diarrhea. Small differences in favor of nitazoxanide were found in comparison with probiotics. Nitazoxanide is an important treatment option for rotavirus diarrhea.
Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. [2009.05.01]
PURPOSE: The effects of nitazoxanide on warfarin pharmacokinetics and pharmacodynamics are examined... CONCLUSION: Coadministration of nitazoxanide twice daily for six days did not affect the pharmacokinetic or pharmacodynamic properties of a single 25-mg dose of warfarin sodium. Administration of a single dose of warfarin or combined administration of a single dose of warfarin and multiple doses of nitazoxanide appeared safe and well tolerated.
Clinical Trials Related to Alinia (Nitazoxanide)
Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients [Recruiting]
The main objective of antiviral therapy of patients with chronic hepatitis C (CHC) is the
sustained elimination of the hepatitis C virus (HCV). The standard of care (SOC) is
peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks according to HCV genotype.
However, this approach is not sufficient to substantially improve the sustained virologic
response (SVR) rates. Therefore, new therapies are needed to treat patients with hepatitis C
virus (HCV) infection. Nitazoxanide (NTZ), originally used to treat cryptosporidium parvum
infection, recently was shown to have an unexpected antiviral activity in the HCV replicon
system and in chronically infected patients.
The aim of this work is to study impact of nitazoxanide therapy in addition to
peginterferon/ribavirin combination on virologic responses in patients with chronic
hepatitis C genotype 4.
Patients will be enrolled in this study and will be randomly assigned in a 1: 1 ratio into 2
groups:
Group A: comprises 100 CHC patients who will receive the standard of care treatment,
peginterferon-alf 2a plus weight-based ribavirin for 48 weeks.
Group B: comprises 100 CHC patients who will receive nitazoxanide monotherapy at a dose of
500 mg twice daily for 12 weeks as a lead-in phase followed by triple therapy, nitazoxanide
500 mg twice daily plus peginterferon alfa-2a, and weight-based ribavirin for 48 weeks.
Data will be collected and statistical analysis will be done comparing the groups regarding
response to antiviral therapy. Final results will be discussed and compared to similar
studies published in peer reviewed journals and international conferences.
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza [Not yet recruiting]
This study is a multicenter randomized factorial double-blind, placebo-controlled trial
designed to evaluate (i) efficacy and safety of nitazoxanide 600 mg administered orally
twice daily for five days compared to a placebo in the treatment of acute uncomplicated
influenza and (ii) efficacy and safety of combination therapy with nitazoxanide 600 mg plus
Oseltamivir 75 mg co-administered orally twice daily for five days compared to nitazoxanide
monotherapy (600 mg b. i.d. for 5 days) and Oseltamivir monotherapy (75 mg b. i.d. for 5 days)
in the treatment of acute uncomplicated influenza.
Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza [Recruiting]
This is a randomized clinical trial designed to evaluate oral nitazoxanide compared to a
placebo in the treatment of acute uncomplicated influenza in adults. We hypothesize that
treatment with nitazoxanide will reduce the duration of symptoms in patients with confirmed
influenza infection. Secondarily, we hypothesize that treatment with nitazoxanide will
reduce the complications of influenza, severity of symptoms, time lost from work, time to
return to normal daily activities, and viral shedding.
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures [Recruiting]
Background:
- Chronic hepatitis C (CHC) is a major health problem that particularly affects
individuals with human immunodeficiency virus (HIV) infection, and can lead to
cirrhosis and liver failure. Standard treatment for people with HIV and CHC is a
48-week course of pegylated-interferon alfa 2a (peg-IFN) and ribavirin (RBV), but
better treatments are needed for those who either do not respond to the drugs or who
relapse after treatment.
- Nitazoxanide has been approved by the Food and Drug Administration primarily to treat
diarrhea caused by parasites, and it has been studied in the treatment of CHC
infection. However, it has not been tested in persons infected with HIV and CHC
co-infection. Researchers are interested in determining whether nitazoxanide is a safe
and tolerable treatment for CHC in individuals with HIV.
Objectives:
- To assess the safety and tolerability of using nitazoxanide to treat chronic hepatitis C
infection in individuals with HIV who have not responded to standard treatment for hepatitis
C.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with both HIV and chronic
hepatitis C, and who have either not responded to or relapsed after previous hepatitis C
treatment.
Design:
- Participants will be screened with a physical examination and medical history; blood
and urine tests; imaging studies; possible heart, lung, and psychological tests; and a
liver biopsy if one has not been done in the past 3 years.
- Participants will receive nitazoxanide, the medication being studied, to take by mouth
for 4 weeks, and will provide blood samples during this time.
- After 4 weeks, participants will receive the first dose of peg-IFN and RBV.
Participants will have weekly injections of peg-IFN and continue to take nitazoxanide
and RBV by mouth for 48 weeks. Individuals who are slow to respond to this combined CHC
treatment (nitazoxanide, peg-IFN, and RBV) by week 12 will continue to have the
combined treatment for an extended period, a total of 72 weeks.
- Participants will have study visits to provide blood samples and have other tests two
times in the first month of combined treatment, and then at months 2, 3, 4, 7, 10, 13,
19; and month 25 only in participants slow to respond to combined treatment.
- Some participants who are on specific HIV treatment regimens may enroll in a substudy
that will require three separate 12-hour visits for repeated blood samples and other
tests ...
Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C [Active, not recruiting]
The purpose of this study is to evaluate the safety and efficacy of
nitazoxanide-peginterferon and nitazoxanide-peginterferon-ribavirin combination regimens
compared to the standard of care (peginterferon-ribavirin) in treating chronic hepatitis C
genotype 4. The study will also evaluate the effect of the studied treatment regimens on end
of treatment virologic response, ALT normalization and safety parameters.
|
